The European Medicines Agency's human medicines committee has recommended refusing a marketing authorisation for Meplyffa (arimoclomol citrate), the drug intended for Niemann-Pick disease type C (NPC) in patients aged two years and over in combination with miglustat. The opinion, adopted on 23 July 2026 and set out in the agency's own record for the medicine, states that efficacy had not been sufficiently demonstrated: because of the way the data had been handled and analysed, the committee found uncertainties about the reliability and robustness of the results, saw no benefit in the ambulation or cognition domains, and did not accept as robust a treatment effect seen in the subgroup of patients who were also taking miglustat. The applicant is Zevra Denmark A/S. An earlier application for the same substance, then called Miplyffa, was withdrawn in March 2022.

The application rested on a 12-month, randomised, double-blind, placebo-controlled phase 2/3 trial (NCT02612129) in 50 children and adolescents aged 2 to 18, randomised 2:1 to arimoclomol or placebo on top of routine care, which for most included miglustat. Forty-two completed. Published in the Journal of Inherited Metabolic Disease in 2021, it reported mean progression on the 5-domain NPC Clinical Severity Scale at 12 months of 0.76 with arimoclomol against 2.15 with placebo. That is one trial, in 50 people, over one year, and it measured a severity score rather than survival.

The United States regulator read the same programme differently. The Food and Drug Administration approved Miplyffa on 20 September 2024 for neurological manifestations of NPC in adults and children aged two and over, in combination with miglustat, on the basis of that 50-patient trial conducted at 14 sites in Europe, Great Britain and the United States; 39 patients taking miglustat as background treatment formed the population described in the label. NPC is a rare inherited lysosomal disorder in which impaired transport of fats inside cells damages the brain and other organs, producing problems with balance, movement and swallowing alongside behavioural change and progressive loss of intellectual function.

Zevra said on 24 July that it would seek a re-examination, and told investors on 5 August that the request has been filed and that 132 patients were enrolled in its global expanded access programme as of 30 June 2026, most of them in Europe according to management's remarks on the results call, where the company said it expects an outcome in the fourth quarter. A re-examination is decided by the CHMP itself and can confirm or reverse the July opinion; it is not an approval. For European families, the practical question in the meantime is not what the drug does but how, if at all, it reaches a given patient, which remains a matter for the treating clinician and the national arrangements that apply.